Overview

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With Previously Untreated HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cance

Status:
Recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as First-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer. At the same time, the correlation between tissue programmed death ligand-1(PD-L1) expression and blood circulating tumor cell(CTC) counts and the efficacy of immune combination therapy was also explored.

Phase:

Phase 2

Details

Lead Sponsor:

Jiuda Zhao

Collaborator:

Second Hospital of Lanzhou University

Treatments:

Apatinib
Oxaliplatin
Tegafur